Alberto Ros-Lozano
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).
Journal: Cephalalgia : an international journal of headache
Published: April 01, 2026
ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.
Journal: Brain and behavior
Published: February 13, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: January 28, 2026
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response.
Journal: The journal of headache and pain
Published: October 31, 2025
Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study.
Journal: Headache
Published: September 06, 2025
Clinical predictors of therapeutic failure of occipital nerve stimulation in refractory chronic cluster headache.
Journal: Cephalalgia : an international journal of headache
Published: June 02, 2024
The profile of refractory chronic cluster headache.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: April 18, 2024
Secondary nummular headache: Are they more common than we thought?
Journal: Headache
Published: March 25, 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 27, 2023
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study.
Journal: European journal of neurology
Published: August 30, 2023
Last Updated: 09/26/2026